Appili Therapeutics Inc.
APLI.TO
TSX
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -58.06% | -21.12% | -10.14% | 34.66% | 1.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.28% | 48.16% | 2.72% | 18.01% | -51.67% |
| Operating Income | 20.97% | -20.70% | -2.72% | -5.20% | 31.08% |
| Income Before Tax | 94.36% | 45.02% | 36.93% | 25.47% | 25.69% |
| Income Tax Expenses | -82.07% | 369.83% | 12.05% | 1,800.00% | 239.19% |
| Earnings from Continuing Operations | 94.20% | 42.01% | 36.71% | 25.26% | 24.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.20% | 42.01% | 36.71% | 25.26% | 24.92% |
| EBIT | 20.97% | -20.70% | -2.72% | -5.20% | 31.08% |
| EBITDA | 21.06% | -20.58% | -2.64% | -5.28% | 31.07% |
| EPS Basic | 94.34% | 42.31% | 52.50% | 56.22% | 56.68% |
| Normalized Basic EPS | 93.88% | 44.62% | 52.42% | 50.22% | 57.21% |
| EPS Diluted | 94.34% | 42.31% | 52.50% | 56.22% | 56.68% |
| Normalized Diluted EPS | 93.88% | 44.62% | 52.42% | 50.22% | 57.21% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 33.19% | 70.16% | 73.05% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 33.19% | 70.16% | 73.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
